These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 7796969)
1. Target and non-target effects of retrovirus vectors used for gene therapy and vaccination. Onions D Dev Biol Stand; 1995; 84():59-74. PubMed ID: 7796969 [No Abstract] [Full Text] [Related]
2. The importance of being RCR. Günzburg WH Curr Opin Mol Ther; 2001 Oct; 3(5):437-8. PubMed ID: 11699887 [No Abstract] [Full Text] [Related]
3. Safety testing programs for gene therapy viral vectors. Ostrove JM Cancer Gene Ther; 1994 Jun; 1(2):125-31. PubMed ID: 7621244 [No Abstract] [Full Text] [Related]
4. Recent advances in retrovirus vector-mediated gene therapy: teaching an old vector new tricks. Weber E; Anderson WF; Kasahara N Curr Opin Mol Ther; 2001 Oct; 3(5):439-53. PubMed ID: 11699888 [TBL] [Abstract][Full Text] [Related]
5. Retroviral vectors for gene therapy of AIDS and cancer. Chang LJ; He J Curr Opin Mol Ther; 2001 Oct; 3(5):468-75. PubMed ID: 11699891 [TBL] [Abstract][Full Text] [Related]
6. Gene transfer with herpes simplex vectors. Lachmann RH; Efstathiou S Curr Opin Mol Ther; 1999 Oct; 1(5):622-32. PubMed ID: 11249669 [TBL] [Abstract][Full Text] [Related]
7. Viral gene therapy strategies: from basic science to clinical application. Young LS; Searle PF; Onion D; Mautner V J Pathol; 2006 Jan; 208(2):299-318. PubMed ID: 16362990 [TBL] [Abstract][Full Text] [Related]
8. DNA vectors. Precedents and safety. Hilleman MR Ann N Y Acad Sci; 1995 Nov; 772():1-14. PubMed ID: 8546382 [No Abstract] [Full Text] [Related]
9. Looking into the safety of AAV vectors. Kay MA; Nakai H Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952 [No Abstract] [Full Text] [Related]
13. Design of retroviral vectors and helper cells for gene therapy. Hu WS; Pathak VK Pharmacol Rev; 2000 Dec; 52(4):493-511. PubMed ID: 11121508 [TBL] [Abstract][Full Text] [Related]
14. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination. Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599 [TBL] [Abstract][Full Text] [Related]
15. A novel human suspension culture packaging cell line for production of high-titre retroviral vectors. Chan LM; Coutelle C; Themis M Gene Ther; 2001 May; 8(9):697-703. PubMed ID: 11406764 [TBL] [Abstract][Full Text] [Related]
16. Packaging cell line DNA contamination of vector supernatants: implication for laboratory and clinical research. Chen J; Reeves L; Sanburn N; Croop J; Williams DA; Cornetta K Virology; 2001 Mar; 282(1):186-97. PubMed ID: 11259201 [TBL] [Abstract][Full Text] [Related]
17. Characterization of live pseudorabies virus vaccines. Kimman TG; Gielkens AL; Glazenburg K; Jacobs L; de Jong MC; Mulder WA; Peeters BP Dev Biol Stand; 1995; 84():89-96. PubMed ID: 7796972 [No Abstract] [Full Text] [Related]
18. Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors. Hlavaty J; Schittmayer M; Stracke A; Jandl G; Knapp E; Felber BK; Salmons B; Günzburg WH; Renner M Virology; 2005 Oct; 341(1):1-11. PubMed ID: 16054668 [TBL] [Abstract][Full Text] [Related]
19. Report to the NIH Recombinant DNA Advisory Committee on murine replication-competent retrovirus (RCR) assays (February 17, 1993). Anderson WF; McGarrity GJ; Moen RC Hum Gene Ther; 1993 Jun; 4(3):311-21. PubMed ID: 8338878 [No Abstract] [Full Text] [Related]
20. Assays to evaluate the genotoxicity of retroviral vectors. Nienhuis AW Mol Ther; 2006 Oct; 14(4):459-60. PubMed ID: 16920033 [No Abstract] [Full Text] [Related] [Next] [New Search]